Fixed-Dose Meropenem-Vaborbactam Available for Complicated UTI, Pyelonephritis

This article originally appeared here.
Share this content:
Meropenem inhibits cell wall synthesis and vaborbactam protects meropenem from degradation by specific serine beta-lactamases.
Meropenem inhibits cell wall synthesis and vaborbactam protects meropenem from degradation by specific serine beta-lactamases.

Vabomere (meropenem and vaborbactam; The Medicines Company) is now available for the treatment of adults (≥18 years old) with complicated urinary tract infections, including pyelonephritis, caused by susceptible Enterobacteriaceae: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex. 

This combination antibiotic includes meropenem, a penem antibacterial, and vaborbactam, a non-suicidal beta-lactamase inhibitor. Meropenem inhibits cell wall synthesis and vaborbactam protects meropenem from degradation by specific serine beta-lactamases; it has no antibacterial activity.

Vabomere for injection is supplied as a sterile powder for constitution in single-dose vials containing meropenem 1 g (equivalent to 1.14 g of meropenem trihydrate) and vaborbactam 1 g. Vabomere does not contain preservatives. Aseptic technique must be used for constitution and dilution.

Reference

Vabomere [package insert] Parsippany, New Jersey: The Medicines Company; 2017.

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters